Iovance Biotherapeutics, Inc.

Fundamentals4.0
Price Action4.0
News Sentiment5.0
AI Rating
5.0

Key Drivers

  • Strong Liquidity
  • Heavy Cash Burn
  • Persistent Losses

AI
AI Summary

5.0

IOVA has moved from a “prove the platform” story to a “prove the ramp” story: revenue and gross margin are improving, but persistent losses, heavy cash burn, and a recent miss mean the stock likely stays under pressure until management shows faster commercial adoption and durable operating leverage.

ExecutionRisk
CommercialRamp‍
MarginExpansion

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

4.0

Key Financial Insights:

  • Strong Liquidity
  • Heavy Cash Burn
  • Persistent Losses

IOVA has a solid liquidity cushion and modest leverage, but persistent losses, heavy cash burn, and negative margins remain the main investment concerns.

liquidity
losses

Price Behavior

4.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Support bounce
  • Failed rally
  • Bearish drift

Over the last month, IOVA bounced from $3.31–$3.40 support to $4.09 but quickly faded into lower highs and lower lows, leaving a cautious near-term setup.

IOVA
technicals
Support Level: $3.31–$3.40
Resistance Level: $3.85–$4.09

Sharp rebound to $4.09 after testing support, then a quick fade

Sentiment & News

5.0

Key News Insights:

  • Revenue miss
  • Raised guidance
  • Share selloff

Iovance posted strong Q1 revenue growth and raised full-year guidance, but a revenue miss and weaker Amtagvi/Proleukin sales triggered a sharp post-earnings selloff.

Biotech

The update is likely negative for near-term sentiment as growth and guidance were overshadowed by weaker sales execution and a steep stock decline